Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
McKesson
Dow
Merck
Express Scripts

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR PROBUPHINE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Probuphine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00447564 ↗ Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence Completed Titan Pharmaceuticals Phase 3 2006-10-01 Buprenorphine (BPN) is an approved treatment for opioid dependence, however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patients with opioid dependence.
NCT00630201 ↗ Extension to Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence Completed Titan Pharmaceuticals Phase 3 2007-10-01 Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine (buprenorphine implant) is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patient with opioid dependence. Patients who have completed 24 weeks of treatment in the Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Probuphine in Patients with Opioid Dependence, will be re-treated with Probuphine over an additional 24 weeks.
NCT00768482 ↗ A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence Terminated Titan Pharmaceuticals Phase 3 2008-09-01 This study will measure the amount of buprenorphine found in the blood after taking sublingual buprenorphine tablets versus after implantation with 4 Probuphine (buprenorphine implants).
NCT00772785 ↗ Study of Probuphine in Patients With Opioid Dependence Terminated Titan Pharmaceuticals Phase 3 2008-09-01 Buprenorphine (BPN) is an approved treatment for opioid dependence; however, in taking oral tablets, patients experience withdrawal and cravings when the variable BPN levels in the blood are low. Probuphine (buprenorphine implant) is an implant placed just beneath the skin that contains BPN. It is designed to provide 6 months of stable BPN blood levels. This study will test the safety and efficacy of Probuphine in the treatment of patients with opioid dependence. Patients who have completed at least 24 weeks of treatment in the Open-Label, Multi-Center Study of Probuphine in Patients with Opioid Dependence (PRO-807 Study), will be re-treated with Probuphine over an additional 24 weeks.
NCT01114308 ↗ A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction Completed National Institute on Drug Abuse (NIDA) Phase 3 2010-04-01 Probuphine (buprenorphine implant) is an implant placed just below the skin containing buprenorphine (BPN). BPN is an approved treatment for opioid dependence. This study will confirm the efficacy of Probuphine vs. placebo and compare Probuphine treatment verses treatment with sublingual buprenorphine in the treatment of patients with opioid dependence.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Probuphine

Condition Name

Condition Name for Probuphine
Intervention Trials
Opioid Dependence 4
Opioid Dependency 3
Head and Neck Squamous Cell Carcinoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Probuphine
Intervention Trials
Opioid-Related Disorders 7
Mucositis 1
Head and Neck Neoplasms 1
Behavior, Addictive 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Probuphine

Trials by Country

Trials by Country for Probuphine
Location Trials
United States 51
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Probuphine
Location Trials
Florida 6
Massachusetts 4
Washington 4
Maryland 4
California 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Probuphine

Clinical Trial Phase

Clinical Trial Phase for Probuphine
Clinical Trial Phase Trials
Phase 3 7
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Probuphine
Clinical Trial Phase Trials
Completed 5
Terminated 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Probuphine

Sponsor Name

Sponsor Name for Probuphine
Sponsor Trials
Titan Pharmaceuticals 7
National Institute on Drug Abuse (NIDA) 1
Braeburn Pharmaceuticals 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Probuphine
Sponsor Trials
Industry 8
NIH 1
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Express Scripts
Harvard Business School
Moodys
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.